The BLAST trial for MRD+ adult B-precursor acute lymphoblastic leukaemia (B-ALL) patients investigates a bi-specific anti-CD19/anti-CD3 BITE® antibody (blinatumomab®)

Graux, Carlos

The BLAST trial for MRD+ adult B-precursor acute lymphoblastic leukaemia (B-ALL) patients investigates a bi-specific anti-CD19/anti-CD3 BITE® antibody (blinatumomab®)

Graux, Carlos

(2012) Belgian Journal of Hematology — Vol. 3, n° 4, p. 155-156 (2012)

Files

GrauxCBelgJHematol2012.pdf

Restricted Access
Adobe PDF
252.23 KB

Request a copy

Details

Authors

Graux, CarlosUCLouvain
Author

Affiliations

UCLouvain(MGD) Service d'hématologie
UCLouvainSSS/IREC/MONT - Pôle Mont Godinne

Citations

APA
Chicago
FWB

Graux, C. (2012). The BLAST trial for MRD+ adult B-precursor acute lymphoblastic leukaemia (B-ALL) patients investigates a bi-specific anti-CD19/anti-CD3 BITE® antibody (blinatumomab®). Belgian Journal of Hematology, 3(4), 155-156. https://hdl.handle.net/2078.5/38693 (Original work published 2012)